Overview
- Sasse, who spoke on 60 Minutes on Sunday, said doctors gave him three to four months in December 2025 but scans now show about a 76% drop in tumor volume and far less pain.
- He is enrolled in a clinical trial of daraxonrasib, an oral therapy from Revolution Medicines that targets cancer‑driving RAS signals.
- Following mid‑April trial updates, the company reported median overall survival of 13.2 months on daraxonrasib compared with 6.7 months on standard chemotherapy.
- The drug is not FDA‑approved and broader access depends on ongoing review, though it holds the agency’s Breakthrough Therapy designation.
- Reported side effects include rashes and gastrointestinal issues, and Sasse described a bleeding facial rash, while investigators say most reactions have been manageable.